Abstract
To study the regulatory effect of atorvastatin (ATV) on the extracellular signal-regulated kinase (ERK) 1/2 pathway and explore its effect on acute myocardial infarction (AMI) rats. The rat model of AMI was established, and the model rats were randomly divided into AMI group and ATV-AMI group, and Sham group was also set up. At 4 weeks after successful modeling, the cardiac function indexes of Sprague-Dawley (SD) rats were detected via magnetic resonance imaging (MRI) and echocardiography (ECG). After the rats were executed, the left ventricular weight index (LVWI) was measured, and the myocardial damage was detected via hematoxylin-eosin (HE) staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining. Moreover, the messenger ribonucleic acid (mRNA) expressions of collagen I and collagen III in myocardial tissues were detected via Real Time-Polymerase Chain Reaction (PCR), and the expressions of ERK1/2 pathway-related proteins in myocardial tissues were detected via Western blotting. After administration of ATV for AMI, the fractional shortening (FS%) and ejection fraction (EF%) were significantly restored. Compared with that in ATV-AMI group, LVWI was significantly increased in AMI group (p<0.05), indicating that ATV could improve the cardiac function after AMI. The results of HE staining and TUNEL staining showed that ATV-AMI group had slighter myocardial damage and significantly lower apoptosis rate than AMI group, indicating that ATV could reverse AMI through the ERK1/2 pathway. Besides, the mRNA expressions of collagen I and collagen III were higher in AMI group and ATV-AMI group than those in Sham group (p<0.05), while they were significantly lower in ATV-AMI group than those in AMI group (p<0.05). The expressions of ERK1/2 pathway-related proteins were also higher in AMI group and ATV-AMI group than those in Sham group (p<0.05). ATV can significantly improve the cardiac function of SD rats after AMI, whose mechanism is related to the expression of the ERK1/2 pathway.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European review for medical and pharmacological sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
